Data on breast cancer resistance protein (BCRP, MXR, ABCG2) expression in acute myeloid leukemia (AML) have been inconsistent, possibly due to use of different assays in different studies. BCRP mRNA was studied by the reverse-transcription polymerase chain reaction and BCRP protein expression (BXP-21, BXP-34 or anti-ABCG2 antibody, with anti-CD34 and anti-CD33) and function (fumitremorgin C modulation of mitoxantrone retention) by flow cytometry in eight cell lines and in pretreatment blasts from 31 AML patients. BCRP mRNA levels, antibody staining and function correlated strongly in cell lines (Pearson r values, 0.73-0.97), but not in AML samples. AML sample BCRP mRNA levels were between those in parental 8226 and 35-fold mitoxantrone-resistant 8226/MR20 cells in all but one case, and BCRP mRNA had the wild-type sequence at codon 482 in all. In AML, unlike in cell lines, BCRP protein expression or function, when present, was only detected in small subpopulations. BCRP mRNA and protein expression did not correlate, nor did staining with different BCRP antibodies, and function did not correlate with mRNA nor protein expression. Presence of BCRP only in subpopulations and discordance among BCRP measurements suggest complex biology of BCRP in AML and incomplete modeling by cell lines.
Introduction
Resistance to structurally unrelated chemotherapy drugs, termed multidrug resistance (MDR), is an obstacle to successful cancer chemotherapy. AML cells frequently overexpress ATP-binding cassette (ABC) transport proteins that function as drug efflux pumps, including P-glycoprotein (Pgp), multidrug resistance protein (MRP-1) and the recently described breast cancer resistance protein (BCRP, MXR, ABCG2). Overexpression of Pgp and MRP-1 in AML cells is associated with treatment failure due to resistant disease. [1] [2] [3] [4] BCRP also confers resistance to drugs used in AML therapy: wild-type BCRP, with arginine at position 482 (BCRP R482 ), effluxes mitoxantrone, and BCRP with mutations that change amino acid 482 to threonine (BCRP R482T ) or glycine (BCRP R482G ) also effluxes anthracyclines. 5 However, the significance of BCRP in AML is unclear, possibly reflecting the use of different assays in different studies. [6] [7] [8] [9] [10] [11] [12] [13] Little is known about the correlation between BCRP assays in AML. We studied expression of wild-type and mutant BCRP mRNA, expression of BCRP protein detected by the three available BCRP-specific monoclonal antibodies and function of BCRP in eight cell lines with different levels of BCRP-mediated resistance and in blasts from 31 untreated AML patients.
Materials and methods

Cell lines
The cell lines were described previously. 6, 7, 14 All cell line experiments were performed with at least five replicates.
Patients
Pretreatment marrow samples from 31 AML patients were selected for study based on the availability of sufficient numbers of cryopreserved cells in the Roswell Park Cancer Institute (RPCI) Leukemia Tissue Bank. Patients received diverse treatment regimens. [15] [16] [17] [18] 
Patient samples
Pretreatment bone marrow samples were enriched for blasts, cryopreserved and thawed as previously described. 15 Quantification of BCRP mRNA: RNA preparation and reverse-transcription polymerase chain reaction A real-time quantitative reverse transcription polymerase chain reaction (RT-PCR) assay for the segment of BCRP mRNA encoding codon 482 (product length 186 bp) and for a segment of b-actin mRNA (product length 238 bp) was performed as previously described. 6, 7 The BCRP mRNA copy number was expressed as copies of BCRP mRNA per pg b-actin mRNA.
BCRP protein expression
Staining with BXP-21 and BXP-34, independently developed antibodies to internal epitopes of BCRP, was performed as previously described. 19 Staining with phycoerythrin (PE)-conjugated anti-ABCG2 (eBioscience, Seattle, WA, USA), which reacts with an external epitope of the protein, was performed on unfixed cells. Cells were incubated on ice with 10% mouse IgG for 10 min, then stained with PE-conjugated anti-ABCG2 or isotype control [PE-Mouse IgG2b (eBioscience)] for 20 min, washed in phosphate-buffered saline and kept on ice until analysis.
BCRP function
BCRP function was studied as previously described. 19 
Two-color analysis of BCRP expression and function
To directly study the relationship between BCRP antibody staining and BCRP activity in patient samples, anti-ABCG2 staining, which did not require cell fixation, and BCRP function were studied by two-color flow cytometry. Cells were processed for BCRP function prior to anti-ABCG2 staining, since anti-ABCG2 at high concentrations may inhibit BCRP function. 20 Briefly, aliquots of cells that had been placed on ice following uptake and following efflux with and without FTC were stained with PE-anti-ABCG2 or with PE-IgG2b isotype control, then washed and placed on ice until analysis. Experiments were performed in triplicate. Cells were also studied for BCRP function and anti-ABCG2 staining separately by single-color flow cytometry as controls for the two-color studies. Antibody staining produced minor changes in mitoxantrone retention that did not alter the evaluation of populations for BCRP expression vs function.
Three-color analysis of BCRP, CD34 and CD33 expression Cells were fixed and then stained with BXP-21 or BXP-34 or isotype control and then with FGAM. 19 They were then washed and stained with PE-Cy5-conjugated CD34 and PE-conjugated CD33. Cells were also stained for 20 min with a panel consisting of PE-conjugated anti-ABCG2, PE-Cy5-conjugated anti-CD33 and fluorescein isothiocyanate (FITC)-conjugated anti-CD34. The isotype control panel consisted of PE-mouse IgG2b, PE-Cy5-mouse IgG1 and FITC-mouse IgG1. To establish compensation settings, cells were also stained with individual antibodies.
Pgp, MRP-1 and LRP expression
Pgp expression was studied on unfixed cells with the MRK16 monoclonal antibody (Kamiya Biomedical Company, Tukwila, WA, USA), as previously described. 15 MRP-1 and LRP were detected with the MRPm6 and LRP56 monoclonal antibodies (Kamiya, Seattle, WA, USA) 21 after cell fixation. 19 Isotype controls were mouse IgG1 for MRPm6 and IgG2b for LRP56 (Caltag, San Francisco, CA, USA). Positive control cell lines were 8226/Dox6 (Pgp), HL60/Adr (MRP-1) and 8226/MR20 (LRP, in addition to BCRP); 14 negative control was HL60. 14 
Flow cytometry
Measurement of antibody staining and mitoxantrone content, data analysis and quantitation by the Kolmogorov-Smirnov (KS) statistic were as previously described. 19 In multicolor analyses, postacquisition compensation was performed to correct fluorescent spectral overlap between fluorochromes. When heterogeneous expression was present, as evident by a broad fluorescence distribution, the entire range of the histogram was used in the KS statistic analysis since no clear boundaries could be assigned to separate populations. In the three-color studies, mononuclear cell gates were created based on forward vs side scatter characteristics, and the size of the subpopulations of cells expressing BCRP was reported as the percentage of the gated mononuclear cells. The CD34/CD33 phenotype of BCRPpositive cells was compared with that of AML blasts in the same bivariate displays as well as with that determined by pretreatment immunophenotyping studies in each case. 22 Because the small size of these subpopulations prohibited accurate assessment of staining intensity by the KS statistic, staining intensity was quantified by the ratio of mean fluorescence intensities of BCRP-positive to -negative cells.
Statistical analysis
Pairwise Pearson's correlation coefficients were estimated, in an exploratory manner, to compare mRNA ratios, transformed with log 10 (1 þ mRNA ratio), and D-values expressed as continuous variables. Cut-off D-values, derived from values that separated positive and negative cell line controls, were used to define the presence or absence of MDR protein expression and BCRP function. D-values Z0.20 defined staining with BXP-21, BXP-34, MRPm6 and LRP56, which are antibodies to intracellular epitopes and are studied following cell fixation, as well as both mitoxantrone efflux and modulation of mitoxantrone efflux by FTC, as previously described. 19 A D-value Z0.10 defined staining with anti-ABCG2 and MRK16, which bind to external epitopes of BCRP and Pgp and thus do not require cell fixation and have a lower background signal. 15 Clinical response to induction therapy was defined as a binary variable, complete remission (CR) vs no CR. CD34-positivity was defined by expression on Z10% of AML cells, as previously described. 22 Linear logistic regression was used to examine the relationship between a binary variable, such as clinical response, and sets of potential predictive variables. The Pearson correlation coefficients were estimated and linear logistic regression was run with the Minitab Statistical package. 23 
Results
Cell lines
BCRP mRNA: BCRP mRNA copies/pg b-actin mRNA ratios in cell lines are shown in Figure 1 . BCRP mRNA was not detected in wild-type HL60 nor in HL60/Adr cells, which overexpress MRP-1. Parental 8226 cells had a BCRP/b-actin mRNA ratio of 34 copies/pg, while 8226/Dox6, with mitoxantrone resistance associated with Pgp as well as BCRP expression, and 8226/MR20, with 35-fold mitoxantrone resistance associated with BCRP overexpression, had ratios of 6020 and 157866 copies/pg, respectively. Wild-type MCF-7 cells had the same level of BCRP mRNA as 8226/MR20 cells. MCF-7 AdVp1000 cells, with 4000-fold resistance, had a BCRP/b-actin mRNA ratio of 1314838 copies/pg, while MCF-7 AdVp3000 cells, with 11000-fold resistance, had a ratio of 1054188 copies/ pg. 8226 and MCF-7 cells expressed wild-type BCRP mRNA, encoding protein with arginine at codon 482 (BCRP R482 ), while MCF-7 AdVp1000 and MCF-7 AdVp3000 cells expressed mutant BCRP encoding protein with threonine at the same position (BCRP R482T ), as detected by the melting temperature of the BCRP PCR hybridization probes. 
BCRP expression and function in AML A Suvannasankha et al
Correlations between BCRP assays: In contrast to the strong correlations in cell lines, BCRP mRNA levels, antibody staining and function correlated poorly in AML samples (Table 2) . BCRP/b-actin mRNA ratios did not correlate with staining with any of the three antibodies, nor with function, and there were no significant correlations among staining with the three antibodies, nor between staining and function. When Dvalues were analyzed as dichotomous variables using cutoff values for positive antibody staining, presence of mitoxantrone efflux and FTC modulation, and a Kappa agreement statistic was estimated for each pairwise relationship, there were no pairwise significant positive agreements between assays.
Two-color analysis of anti-ABCG2 staining and BCRP function: Two-color flow cytometry experiments demonstrated that BCRP expression and function were present in subpopulations of AML blasts. In 10 samples (32%), subpopulations of AML blasts stained with anti-ABCG2, but did not exhibit mitoxantrone efflux nor FTC modulation, while in three cases (10%), mitoxantrone efflux was present and was modulated by FTC, but the cells did not stain with anti-ABCG2 (Figure 3 ). In two cases (6%) mitoxantrone efflux with modulation by FTC and anti-ABCG2 staining were both present, but in separate subpopulations. Anti-ABCG2 staining and FTC modulation of mitoxantrone retention were not seen in the same subpopulation BCRP/β-actin mRNA Table 2 Correlations between BCRP mRNA, staining with the three BCRP-specific monoclonal antibodies BXP- Three-color analysis of antibody staining Correlation between BCRP and clinical outcome: Due to the small number of patients in this series and the heterogeneity of treatment, correlation of BCRP expression and function with treatment outcome was not a primary objective of the study, but was included in exploratory analyses. The relationship between induction therapy outcome [complete remission (CR) vs no CR] and BCRP mRNA (log transform), BXP-21, BXP-34 and anti-ABCG2 staining and FTC modulation of mitoxantrone efflux was explored with logistic regression. Anti-ABCG2 staining was a significant explanatory variable (P ¼ 0.012); as the anti-ABCG2 staining D-value increases, the probability of a CR decreases.
Discussion
We analyzed BCRP mRNA expression, protein expression detected by three BCRP-specific antibodies, and function in cell lines with diverse levels of resistance and in AML marrow samples. BCRP measurements correlated well in cell lines, but not in AML samples. One explanation is BCRP expression only in small subpopulations in AML samples, in contrast to the homogeneous expression in cell lines. Additionally, however, lack of correlation between BCRP expression and function in AML subpopulations was directly demonstrated by two-color flow cytometry. Our study confirms a previous report that BCRP is expressed only in AML subpopulations, 12 but does not confirm association with CD34 expression. 11 Moreover, by three-color flow cytometric analysis, there was no consistent pattern of CD34 and/or CD33 expression in AML subpopulations expressing BCRP. BCRP expression in AML cells might vary depending on the stage of the stem cells in which malignant transformation occurred. In this regard, side population (SP) stem cells, which are CD34-and are more primitive than CD34 þ cells, express high levels of BCRP mRNA, 24 and BCRP is downregulated during differentiation of normal stem cells, becoming undetectable in mature granulocytes. Alternatively, BCRP may be aberrantly expressed in AML, consistent with the aberrant maturation generally seen. 22 Differential activity of Pgp in AML has been suggested based on cellular maturation; 25 specifically Pgp may be active in CD34 þ cells, but not in CD33 þ cells. This phenomenon was not seen with BCRP in our study.
In this small series of heterogeneously treated patients, low anti-ABCG2 antibody staining correlated with attainment of CR, but other BCRP parameters did not. Since BCRP function did not correlate with expression in AML cells nor with outcome, the apparent association between anti-ABCG2 staining and outcome might reflect a mechanism other than drug efflux. Of note, Pgp has been shown to have efflux-independent effects in AML cells. 26 The biology of BCRP expression and function in AML is more complex than in cell line models. Our study highlights these complexities, but further studies are needed to decide on an optimal approach to analysis of BCRP in clinical samples. As with Pgp, 27 development of consensus recommendations for the standardization of BCRP detection would be beneficial in advancing the field. Two-color flow cytometric analysis of BCRP expression and function in AML samples. The top row of histograms shows an example of a patient sample with anti-ABCG2 staining (circle) but no mitoxantrone efflux nor FTC modulation (circle). The bottom row of histograms shows an example of a patient sample in which mitoxantrone efflux was present (circle) and was modulated by FTC (circle), but staining with anti-ABCG2 was not seen. Histogram regions are defined by anti-ABCG2 isotype labeling (x-axis) and mitoxantrone uptake (y-axis).
